- Structural heart company Anteris Technologies (AVR) has received a United States patent for its sterilisation method
- The sterilisation method can be used with a collagen-based biomaterial and was invented by Professor Leon Neething
- Sterilisation is an important step in the company’s ADAPT tissue technology process and is a key in its manufacturing of ADAPT
- On the market this afternoon, Anteris is down 0.25 per cent and is trading for $3.99 per share
Structural heart company Anteris Technologies (AVR) has received a United States patent for its sterilisation method.
The patent was granted by the United States Patent Office. The sterilisation method can be used with a collagen-based biomaterial and was invented by Professor Leon Neething. Leon is currently the Vice President of Cardiovascular Technologies at Anteris and is also a professor ar School of Surgery in the University of Western Australia.
Sterilisation is an important step in the company’s ADAPT tissue technology process and is a key in its manufacturing of ADAPT.
ADAPT tissue platform is a next-generation technology with zero DNA and zero glutaraldehyde (Cidex). It is the only bio-scaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery.
“Expanding our intellectual property portfolio is an area of continual focus,” Chief Executive Officer Wayne Paterson said.
“The ADAPT tissue is a vital component of our DuraAVR single-piece 3D aortic valve, and therefore extending the IP portfolio is essential to our value creation strategy,” he added.
On the market this afternoon, Anteris is down 0.25 per cent and is trading for $3.99 per share at 2:43 pm AEST.